Chen J, Dai W, Wang H, Lei W, Fang G, Dai D
Genes (Basel). 2024; 15(10).
PMID: 39457377
PMC: 11508147.
DOI: 10.3390/genes15101253.
Benyamini P
Antibiotics (Basel). 2024; 13(10).
PMID: 39452186
PMC: 11504868.
DOI: 10.3390/antibiotics13100919.
Gadar K, McCarthy R
NPJ Antimicrob Resist. 2024; 1(1):11.
PMID: 38686217
PMC: 11057201.
DOI: 10.1038/s44259-023-00011-6.
Dutt Y, Dhiman R, Singh T, Vibhuti A, Gupta A, Pandey R
Antibiotics (Basel). 2022; 11(7).
PMID: 35884186
PMC: 9312340.
DOI: 10.3390/antibiotics11070930.
Rather M, Gupta K, Mandal M
Braz J Microbiol. 2021; 52(4):1701-1718.
PMID: 34558029
PMC: 8578483.
DOI: 10.1007/s42770-021-00624-x.
Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections.
Loubet P, Ranfaing J, Dinh A, Dunyach-Remy C, Bernard L, Bruyere F
Front Microbiol. 2020; 11:1509.
PMID: 32719668
PMC: 7350282.
DOI: 10.3389/fmicb.2020.01509.
Small Molecule Anti-biofilm Agents Developed on the Basis of Mechanistic Understanding of Biofilm Formation.
Qvortrup K, Hultqvist L, Nilsson M, Jakobsen T, Jansen C, Uhd J
Front Chem. 2019; 7:742.
PMID: 31737611
PMC: 6838868.
DOI: 10.3389/fchem.2019.00742.
The small molecule nitazoxanide selectively disrupts BAM-mediated folding of the outer membrane usher protein.
Psonis J, Chahales P, Henderson N, Rigel N, Hoffman P, Thanassi D
J Biol Chem. 2019; 294(39):14357-14369.
PMID: 31391254
PMC: 6768635.
DOI: 10.1074/jbc.RA119.009616.
Therapeutic Approaches Targeting the Assembly and Function of Chaperone-Usher Pili.
Psonis J, Thanassi D
EcoSal Plus. 2019; 8(2).
PMID: 30873935
PMC: 6422168.
DOI: 10.1128/ecosalplus.ESP-0033-2018.
A review on anti-adhesion therapies of bacterial diseases.
Asadi A, Razavi S, Talebi M, Gholami M
Infection. 2018; 47(1):13-23.
PMID: 30276540
DOI: 10.1007/s15010-018-1222-5.
Phenotypic Variation during Biofilm Formation: Implications for Anti-Biofilm Therapeutic Design.
Beitelshees M, Hill A, Jones C, Pfeifer B
Materials (Basel). 2018; 11(7).
PMID: 29949876
PMC: 6073711.
DOI: 10.3390/ma11071086.
Pili Assembled by the Chaperone/Usher Pathway in and .
Werneburg G, Thanassi D
EcoSal Plus. 2018; 8(1).
PMID: 29536829
PMC: 5940347.
DOI: 10.1128/ecosalplus.ESP-0007-2017.
Development of Protein-Protein Interaction Inhibitors for the Treatment of Infectious Diseases.
Voter A, Keck J
Adv Protein Chem Struct Biol. 2018; 111:197-222.
PMID: 29459032
PMC: 6201748.
DOI: 10.1016/bs.apcsb.2017.07.005.
UroPathogenic (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-antibiotic Antimicrobial Strategies.
Terlizzi M, Gribaudo G, Maffei M
Front Microbiol. 2017; 8:1566.
PMID: 28861072
PMC: 5559502.
DOI: 10.3389/fmicb.2017.01566.
Current Research Approaches to Target Biofilm Infections.
van Tilburg Bernardes E, Lewenza S, Reckseidler-Zenteno S
Postdoc J. 2017; 3(6):36-49.
PMID: 28748199
PMC: 5524445.
DOI: 10.14304/surya.jpr.v3n6.5.
Small Molecules That Sabotage Bacterial Virulence.
Johnson B, Abramovitch R
Trends Pharmacol Sci. 2017; 38(4):339-362.
PMID: 28209403
PMC: 5679398.
DOI: 10.1016/j.tips.2017.01.004.
The arsenal of pathogens and antivirulence therapeutic strategies for disarming them.
Brannon J, Hadjifrangiskou M
Drug Des Devel Ther. 2016; 10:1795-806.
PMID: 27313446
PMC: 4890686.
DOI: 10.2147/DDDT.S98939.
Peptidomimetic Small Molecules Disrupt Type IV Secretion System Activity in Diverse Bacterial Pathogens.
Shaffer C, Good J, Kumar S, Krishnan K, Gaddy J, Loh J
mBio. 2016; 7(2):e00221-16.
PMID: 27118587
PMC: 4850256.
DOI: 10.1128/mBio.00221-16.
The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation.
Langdon A, Crook N, Dantas G
Genome Med. 2016; 8(1):39.
PMID: 27074706
PMC: 4831151.
DOI: 10.1186/s13073-016-0294-z.
Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.
OBrien V, Hannan T, Nielsen H, Hultgren S
Microbiol Spectr. 2016; 4(1).
PMID: 26999391
PMC: 4887100.
DOI: 10.1128/microbiolspec.UTI-0013-2012.
